We evaluated whether whole-body dual-energy X-ray absorptiometry (DXA) measures of
lean body mass can be used as biomarkers for disease progression and treatment effects in …

Steroids are nowadays routinely used as a long-term treatment in Duchenne muscular
dystrophy (DMD). Their effects on body composition were assessed using dual X-ray …

Objective A number of promising experimental therapies for Duchenne muscular dystrophy
(DMD) are emerging. Clinical trials currently rely on invasive biopsies or motivation …

Results: Medical records (n= 193) were examined from which 75% were included for
analysis. The mean age of the cohort at the time of data collection was 11.9 years, with 72 …

The development of new therapeutic agents for the treatment of Duchenne muscular
dystrophy has put a focus on defining outcome measures most sensitive to capture treatment …

ABSTRACT Introduction: In Duchenne muscular dystrophy (DMD), fat replacement of muscle
may be a useful endpoint in trials of therapy, although progression in different muscle …

Serum metabolite profiling in Duchenne muscular dystrophy (DMD) may enable discovery of
valuable molecular markers for disease progression and treatment response. Serum …

There is a pressing need for biomarkers and outcomes that can be used across disease
stages in Duchenne muscular dystrophy (DMD), to facilitate the inclusion of a wider range of …

Background: Duchenne muscular dystrophy (DMD) is a severe X-linked neuromuscular
disorder. Young people with DMD have high rates of obesity. There is emerging evidence …

Duchenne muscular dystrophy (DMD) is a progressive, neuromuscular disorder caused by
mutations in the DMD gene that results in a lack of functional dystrophin protein. Herein, we …